Android app on Google Play

VIVUS, Inc. (VVUS) Qsymia Prescriptions Show Gains During Slow Holiday Week (ARNA) (OREX)

February 4, 2013 10:45 AM EST Send to a Friend
Get Alerts VVUS Hot Sheet
Price: $5.25 +4.58%

Rating Summary:
    4 Buy, 7 Hold, 5 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 34 | Down: 12 | New: 36
Trade VVUS Now!
Join SI Premium – FREE
VIVUS, Inc. (Nasdaq: VVUS) is lower on the session amid new data for prescriptions of its weight-loss pill, Qsymia.

According to Bloomberg Industries, Qsymia prescriptions rose 24 percent to 2,859 last week. Data comes from Symphony Health Solutions.

Bloomberg also noted that the shortened holiday week (MLK Day) saw its retail prescription index fall nine percent.

The news comes as peer Arena Pharma (Nasdaq: ARNA) and its partner Eisai are planning to debut competing obesity pill Belviq soon. Orexigen (Nasdaq: OREX), which is developing Contrave as a weight-loss pill, is still in testing phases.

VIVUS is off about 0.4 percent Monday morning.




You May Also Be Interested In


Related Categories

Analyst Comments, FDA

Add Your Comment